Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Psoriasis organizations ... patients with lived experience, and information from top institutions. Susan Bard, MD, is a clinical instructor in the department of dermatology at Weill Cornell ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

Join Drs Steven Feldman and Robert Kushner as they discuss the role of dermatologists in treating obesity in conjunction with psoriasis.

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

A study finds that 99% of dietary advice for psoriasis on Instagram is low-quality, often unsubstantiated and posted by ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...